|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | CONSORT 2010说明与详述:报告平行对照随机临床试验指南的更新显示文摘大量证据显示随机对照临床试验(randomised controlled trial,RCT)的报告质量不理想。报告不透明,则读者既不能评判试验结果是否真实可靠,也不能从中提取可用于系统综述的信息。最近的方法学分析表明,报告不充分和设计不合理与对治疗效果产生评价偏倚有关。这种系统误差对RCT损害严重,而RCT正是以其能减少或避免偏倚而被视为评价干预措施的金标准。为了提高RCT的报告质量,一个由专家和编辑组成的工作组制定了临床试验报告的统一标准(Consolidated Standards of Reporting Trials,CONSORT)声明。CONSORT声明于1996年首次发表,并于2001年更新。声明由对照检查清单和流程图组成,供作者在报告RCT时使用。许多核心医学期刊和主要国际性编辑组织都已认可CONSORT声明。该声明促进了对RCT的严格评价和解释。2001年,在对CONSORT进行修订时,人们就已经清楚地认识到,解释和说明制定CONSORT声明的原理,有助于研究人员等撰写或评价临床试验报告。一篇CONSORT说明与详述文章于2001年同2001版CONSORT声明一起发表。2007年1月的专家会议之后,对CONSORT声明作了进一步修订并已发表,即'CONSORT2010声明'。这次更新对原版对照检查清单作了文字上的修改,使其更为明晰,并收入了与一些新近才认识到的主题相关的建议,如选择性报告结局产生的偏倚。说明与详述文件旨在加强人们对CONSORT声明的理解、应用和传播,这次也作了大量修订,对每一项新增或更新的清单条目的含义和增改理由进行了解释,提供了优秀的报告实例,还尽可能地提供了相关的经验性研究的参考文献。文中收入了若干流程图实例。'CONSORT2010声明'、其说明与详述文件,以及相关网站(www.consort-statement.org),对于改进随机临床试验报告必将有所裨益。 | David Moher Sally Hopewell Kenneth F Schulz Victor Montori Peter C Gφtzsche P J Devereaux Diana Elbourne Matthias Egger Douglas G Altman 周庆辉 卞兆祥 刘建平 | 2010 | 中西医结合学报2010，8，8： | 318 |
| 2 | Role of inflammation and infection in the pathogenesis of human acute liver failure: clinical implications for monitoring and therapy显示文摘Acute liver failure is a rare and devastating clinical condition. At present, emergency liver transplantation is the only life-saving therapy in advanced cases, yet the feasibility of transplantation is affected by the presence of systemic inflammation, infection and resultant multiorgan failure. The importance of immune dysregulation and acquisition of infection in the pathogenesis of acute liver failure and its associated complications is now recognised. In this review we discuss current thinking regarding the role of infection and inflammation in the pathogenesis of and outcome in human acute liver failure, the implications for the management of such patients and suggest directions for future research. | Mhairi C Donnelly Peter C Hayes Kenneth J Simpson | 2016 | World Journal of Gastroenterology2016，22，26： | 13 |
| 3 | Highly efficient derivation of ventricular cardiomyocytes from induced pluripotent stem cells with a distinct epigenetic signature显示文摘从 pluripotent 干细胞导出的 Cardiomyocytes 能在药测试,疾病建模和基于房间的治疗被使用。没有 procardiogenic 生长因素,然而,从 pluripotent 干细胞的 cardiomyogenesis 的效率通常是低的,产生 cardiomyocyte 人口是异构的。这里,我们证明导致的 pluripotent 干细胞( iPSCs )能从鼠科的室的 myocytes ( VM )被导出,并且与从各种各样的体的房间类型导出的 iPSCs 的另外的报告一致,自发地作为与遗传上匹配的胚胎的干细胞(转换字符)或 iPSCs 相比区分 cardiomyocytes 进跳动的显著地更高的倾向从尾巴尖端成纤维细胞导出的 导出VM 的 iPSCs ( ViPSCs )展览。惊人地,导出 ViPSC 的 cardiomyocytes 显示的多数室的显型。在 ViPSCs 的提高的室的 myogenesis 在区别的早阶段经由心血管的祖先的增加的数字被调停。以便从 ViPSCs 调查提高的室的 myogenesis 的机制,我们执行了全球基因表示和 DNA methylation 分析,它揭示了可以涉及在 pluripotent 干细胞指定 VM 命运的不同 epigenetic 签名。 | Huansheng Xu B Alexander Yi Hao Wu Christoph Bock Hongcang Gu Kathy O Lui Joo-Hye C Park Ying Shao Alyssa K Riley Ibrahim J Domian Erding Hu Robert Willette John Lepore Alexander Meissner Zhong Wang Kenneth R Chien | 2012 | Cell Research2012，22，1： | 7 |
| 4 | Stem cell therapy for the treatment of Leydig cell dysfunction in primary hypogonadism显示文摘The production of testosterone occurs within the Leydig cells of the testes. When production fails at this level from either congenital, acquired, or systemic disorders,the result is primary hypogonadism. While numerous testosterone formulations have been developed, none are yet fully capable of replicating the physiological patterns of testosterone secretion. Multiple stem cell therapies to restore androgenic function of the testes are under investigation. Leydig cells derived from bone marrow, adipose tissue, umbilical cord, and the testes have shown promise for future therapy for primary hypogonadism. In particular, the discovery and utilization of a group of progenitor stem cells within the testes, known as stem Leydig cells(SLCs), has led not only to a better understanding of testicular development, but of treatment as well. When combining this with an understanding of the mechanisms that lead to Leydig cell dysfunction, researchers and physicians will be able to develop stem cell therapies that target the specific step in the steroidogenic process that is deficient. The current preclinical studies highlight the complex nature of regenerating this steroidogenic process and the problems remain unresolved. In summary, there appears to be two current directions for stem cell therapy in male primary hypogonadism. The first method involves differentiating adult Leydig cells from stem cells of various origins from bone marrow, adipose, or embryonic sources. The second method involves isolating, identifying, and transplanting stem Leydig cells into testicular tissue. Theoretically, in-vivo re-activation of SLCs in men with primary hypogonadism due to age would be another alternative method to treat hypogonadism while eliminating the need for transplantation. | Taylor C Peak Nora M Haney William Wang Kenneth J DeLay Wayne J Hellstrom | 2016 | World Journal of Stem Cells2016，8，10： | 5 |
| 5 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial显示文摘 | Michael P Manns John G McHutchison Stuart C Gordon Vinod K Rustgi Mitchell Shiffman Robert Reindollar Zachary D Goodman Kenneth Koury Mei-Hsiu Ling Janice K Albrecht | 2001 | The Lancet2001，，9286： | 4 |
| 6 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial显示文摘 | Michael P Manns John G McHutchison Stuart C Gordon Vinod K Rustgi Mitchell Shiffman Robert Reindollar Zachary D Goodman Kenneth Koury Mei-Hsiu Ling Janice K Albrecht | 2001 | The Lancet . 2001 (9286)2001，，9286： | 4 |
| 7 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial显示文摘 | Michael P Manns John G McHutchison Stuart C Gordon Vinod K Rustgi Mitchell Shiffman Robert Reindollar Zachary D Goodman Kenneth Koury Mei-Hsiu Ling Janice K Albrecht | 2001 | 2001 (9286)2001，，9286： | 4 |
| 8 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 3 |
| 9 | Evaluation of Burkholdderia cepacia strains:Root colonization of Catharanthus roseus and in vitro inhibition of selected of soil borne fungal pathogens 显示文摘 | Mansour B Martin A D Kenneth E C | 1999 | Proceedings of the Oklahoma Academy of Science1999，79，： | 3 |
| 10 | Structure of the Ca2+-dependent PP2A heterotrimer and insights into Cdc6 dephosphorylation显示文摘B″蛋白质磷酸酶 2A (PP2A ) 的 /PR72 家庭一个重要 PP2A 家庭涉及多样的细胞的过程,并且特别地由钙绑定调整了到规章的子单元。在这个家庭的 PR70 子单元与房间部门控制 6 交往(Cdc6 ) ,为 DNA 复制的控制重要的一个房间周期管理者。这里,我们在 2.1 和 2.4 Å 的一个决定报导孤立的 PR72 和 trimeric PR70 holoenzyme 的水晶结构;,分别地并且在 Cdc6 dephosphorylation 的 vitro 描述。holoenzyme 结构表明 PR70 钙绑定主题之一直接联系支架子单元,导致在所有 PP2A holoenzymes 之中的最紧缩的支架子单元符合构造。PR70 也在活跃地点附近区别地绑在催化子单元,它被要求让 PR70 向 Cdc6 提高磷酸酶活动。我们的研究为 B″ 的唯一的规定提供一个结构的基础;由钙离子的 /PR72 holoenzymes,并且在 PP2A holoenzymes 之中为底层特性的精确控制建议机制。 | Nathan Wlodarchak Feng Guo Kenneth A Satyshur Li Jiang Philip D Jeffrey Tingwan Sun Vitali Stanevich Marc C Mumby Yongna Xing | 2013 | Cell Research2013，23，7： | 3 |
| 11 | Response to strict and liberalized specific carbohydrate dietin pediatric Crohn's disease显示文摘AIM: To investigate the specific carbohydrate diet(SCD) as nutritional therapy for maintenance of remission in pediatric Crohn's disease(CD). METHODS: Retrospective chart review was conducted in 11 pediatric patients with CD who initiated the SCD as therapy at time of diagnosis or flare. Two groups defined as SCD simple(diet alone, antibiotics or 5-ASA) or SCD with immunomodulators(corticosteroids and/or stable thiopurine dosing) were followed for one year and compared on disease characteristics, laboratory values and anthropometrics.RESULTS: The mean age at start of the SCD was 11.8 ± 3.0 years(range 6.6-17.6 years) with five patients starting the SCD within 5 wk of diagnosis. Three patients maintained a strict SCD diet for the study period and the mean time for liberalization was 7.7 ± 4.0 mo(range 1-12) for the remaining patients. In both groups, hematocrit, albumin and ESR values improved while on strict SCD and appeared stable after liberalization(P-value 0.006, 0.002, 0.002 respectively). The majority of children gained in weight and height percentile while on strict SCD, with small loss in weight percentile documented with liberalization. CONCLUSION: Disease control may be attainable with the SCD in pediatric CD. Further studies are needed to assess adherence, impact on mucosal healing and growth. | Jennifer C Burgis Kaylie Nguyen KT Park Kenneth Cox | 2016 | World Journal of Gastroenterology2016，22，6： | 3 |
| 12 | OPCML对卵巢癌细胞抑制的体内外实验研究显示文摘目的探讨OPCML在体外、体内对卵巢癌细胞的影响。方法将OPCML用重组慢病毒转导入人卵巢癌细胞A2780、OCC1和正常小鼠卵巢上皮细胞CD1。通过细胞增殖试验、细胞聚合力试验、细胞周期的分析和体内成瘤试验等来研究OPCML在卵巢癌细胞中的功能。结果(1)OPCML能被重组慢病毒高效地转导入靶细胞,转导效率几乎达100%,同时达到稳定的表达,Westernblot能检测到OPCML(60kDa)和GFP(27kDa)基因蛋白在靶细胞中的表达;(2)在A2780细胞系,转导入OPCML后的细胞(A2780-OPCML)的增殖明显的比未转基因(A2780)或仅转空载体(A2780-pWPI)者慢(P<0.01),但在OCC1和CD1细胞系,OPCML对细胞的增殖无明显的影响(P>0.05);(3)用流式细胞仪法对细胞周期分析显示,OPCML对A2780的细胞周期有明显的滞留作用(P<0.05),但对OCC1、CD1细胞则无明显滞留作用;(4)细胞聚合力试验提示OPCML能明显增强细胞的粘附力;(5)表达OPCML的A2780细胞在裸鼠皮下仅有一个(1/4)有肿瘤生长,体积显著小于A2780及A2780-pWPI组(4/4)(P<0.001),免疫组织化学染色法能够检测到OPCML蛋白在肿瘤组织中的表达。结论慢病毒载体作为转基因的工具,具有高效转导率和稳定表达的特点;OPCML能够增加细胞的粘附能力,抑制A2780的增殖和体内成瘤,提示OPCML可能是一个新的抑癌基因。 | 姚德生 李力 Kenneth Garson Barbara C Vanderhyden | 2007 | 肿瘤防治研究2007，34，2： | 2 |
| 13 | Evolution of endovascular mechanical thrombectomy for acute ischemic stroke显示文摘Acute ischemic stroke(AIS) is a common medical problem associated with significant morbidity and mortality worldwide. A small proportion of AIS patients meet eligibility criteria for intravenous thrombolysis(IVT) with recombinant tissue plasminogen activator, and its efficacy for large vessel occlusion is poor. Therefore, an increasing number of patients with AIS are being treated with endovascular mechanical thrombectomy when IVT is ineffective or contraindicated. Rapid advancement in catheter-based and endovascular device technology has led to significant improvements in rates of cerebral reperfusion with these devices. Stentrievers and modern aspiration catheters have now surpassed earlier generation devices in the degree and rapidity of revascularization. This progress has been achieved with no concurrent increase in risk of major complications or mortality, both when used alone or in combination with IVT. The initial randomized controlled trials comparing endovascular therapy to IVT for AIS failed to show superior outcomes with endovascular treatment, butkey limitations of each trial may limit the significance of these results to current practice. While endovascular devices and operator experience continue to evolve, we are optimistic that this will be accompanied by improvements in patient outcomes. This review highlights the major endovascular devices used in current practice and the trials which have investigated their efficacy. | Colin J Przybylowski Dale Ding Robert M Starke Christopher R Durst R Webster Crowley Kenneth C Liu | 2014 | World Journal of Clinical Cases2014，2，11： | 2 |
| 14 | A fern that hyperaccumulates arsenic显示文摘 | Ma L Q Kenneth M K Tu C | 2001 | Nature2001，409，6820： | 1 |
| 15 | Recognition and management of cardiac arrhythmias显示文摘 | Simon C Kenneth M K | 1995 | Curr Probl Cardiol1995，20，2： | 1 |
| 16 | A finite element technique for the ultimate strength analysis of tubular joints 显示文摘 | William F C Kenneth M W | 1992 | Engineering Computations1992，9，3： | 1 |
| 17 | Numerical Modeling of Concrete Confined by Fiber-Reinforced Composites显示文摘 | Malvar L J Kenneth B M John E C | 2004 | Journal of Composites for Construction2004，8，4： | 1 |
| 18 | COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention 显示文摘 | Mary C C Kenneth J O John V R | 2012 | Biochim Biophys Acta2012，1825，1： | 1 |
| 19 | Bulimia: Medical Complications 显示文摘 | Philif SM Cynthia C Kenneth W | 2004 | J Women''s Health2004，13，6： | 1 |
| 20 | Thalidomide and immunomodulatory drugs as cancer therapy显示文摘 | Raje N Kenneth C | 2002 | Oncology2002，14，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员